Drug Update · Oncology

FDA Approves datopotamab deruxtecan for EGFR‑mutant NSCLC: 45% ORR

July 19, 2026

Approval date

2025-01-17

Indication

Adult patients with locally advanced or metastatic EGFR‑mutated NSCLC after prior EGFR‑directed therapy and platinum-based chemotherapy

Primary efficacy (ORR)

45% (pooled TROPION-Lung05 and TROPION-Lung01 EGFR‑mutated subgroup) [12]

Median DOR

6.5 months (pooled EGFR‑mutated subgroup) [12]

Recommended dose

6 mg/kg IV once every 3 weeks (FDA‑approved dosing) [6]

Clinical Perspective

Clinicians treating medical oncologists and thoracic oncology teams who manage patients with EGFR‑mutated NSCLC now have an FDA‑approved Trop‑2‑directed antibody‑drug conjugate option for adult patients who have received prior EGFR‑directed therapy and platinum‑based chemotherapy. The accelerated approval was granted on the basis of a pooled ORR of 45% and a median DOR of 6.5 months, supporting antitumor activity in a heavily pretreated EGFR‑mutated subgroup ^[3]. Key prescribing considerations include the FDA‑approved dose (6 mg/kg intravenously every 3 weeks), premedication and ophthalmic monitoring, and vigilance for ILD/pneumonitis and stomatitis as described in the prescribing information ^[2]^[3].

Dr. Meera Pillai · Oncology

The FDA approved datopotamab deruxtecan (DATROWAY) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy on 2025-01-17, based on pooled data from the TROPION-Lung05 and TROPION-Lung01 analyses showing a 45% objective response rate (ORR) in the EGFR-mutated subgroup ^[3]^[1]. The approval is an accelerated approval contingent on verification of clinical benefit in confirmatory trials ^[2]^[3].

Clinical Context

Datopotamab deruxtecan is a Trop‑2-directed antibody‑drug conjugate that delivers a potent topoisomerase I inhibitor payload (DXd) after antibody-mediated internalization and lysosomal linker cleavage; the ADC produced antitumor activity in preclinical lung cancer models and is manufactured by Daiichi Sankyo ^[1]^[3]. The FDA indication specifically targets adult patients with locally advanced or metastatic EGFR‑mutated NSCLC after prior EGFR‑directed therapy and platinum-based chemotherapy; this approval followed single-arm and randomized clinical program data from TROPION-Lung05 (phase II) and TROPION-Lung01 (randomized) that included an EGFR‑mutated subgroup evaluated by blinded independent central review (BICR) ^[1]^[3]. The FDA prescribing information and highlights describe dosing, premedication, monitoring, and warnings including interstitial lung disease/pneumonitis and ocular effects ^[2]^[3].

Key Findings

The pooled analysis of TROPION-Lung05 and TROPION-Lung01 showed DATROWAY achieved an objective response rate (ORR) of 45% in patients with EGFR‑mutated locally advanced or metastatic NSCLC (pooled N=114) by BICR per RECIST v1.1 ^[3].
Median duration of response (DOR) in the pooled EGFR‑mutated population was 6.5 months (95% CI, 4.2 to 8.4) ^[3].
The TROPION-Lung05 phase II trial (single-arm) evaluated Dato-DXd and reported a confirmed ORR of 35.8% overall; in the subgroup with EGFR mutations the confirmed ORR was 43.6% (95% CI, 32.4 to 55.3) in that study cohort ^[1].
The FDA approval was granted under accelerated approval based on ORR and DOR; continued approval may depend on verification in confirmatory trials ^[2]^[3].

Safety & Tolerability

Interstitial lung disease (ILD)/pneumonitis: DATROWAY can cause severe and fatal ILD/pneumonitis; in pooled NSCLC safety datasets and trials ILD/pneumonitis events were observed and the label warns to monitor for new or worsening respiratory symptoms and to withhold or permanently discontinue as indicated ^[2]^[3].
Stomatitis/oral mucositis: Stomatitis was the most common treatment‑related adverse event in trials (any grade 56.2%; grade ≥3 9.5%) and is specifically described in the clinical trial report and label ^[1]^[2].
Grade ≥3 treatment‑related adverse events occurred in 28.5% of patients in the TROPION-Lung05 trial population; specific grade 5 ILD/pneumonitis events were reported (one grade 5 event; 0.7% in that trial) ^[1].
Ocular adverse reactions: the prescribing information lists ocular events including dry eye, keratitis, blepharitis, meibomian gland dysfunction, increased lacrimation, conjunctivitis, and blurred vision and recommends ophthalmic monitoring and supportive care ^[2].
Common adverse reactions (≥20%) reported in the EGFR‑mutated NSCLC population included stomatitis, nausea, alopecia, fatigue, decreased hemoglobin, decreased lymphocytes, constipation, increased AST, decreased white blood cell count, increased lactate dehydrogenase, musculoskeletal pain, decreased appetite, increased ALT, and rash as described in the label and highlights ^[2].

Study Design

The FDA indication was supported by clinical activity observed in the TROPION program, including TROPION-Lung05, a phase II single‑arm trial of datopotamab deruxtecan in previously treated advanced/metastatic NSCLC with actionable genomic alterations, and TROPION-Lung01, a randomized open‑label trial; the approval documents report a pooled EGFR‑mutated subgroup analysis (TROPION-Lung05 and TROPION-Lung01 pooled, N=114) with ORR by blinded independent central review per RECIST v1.1 ^[1]^[3]. Patients in the NSCLC studies received DATROWAY at the FDA‑approved dose of 6 mg/kg once every 3 weeks; detailed trial eligibility and design elements appear in the published trial report and FDA review documents ^[1]^[3]. Clinicians should consult current prescribing information for full dosing guidance.

FAQ

Q1 What is datopotamab deruxtecan (DATROWAY) approved for?

Datopotamab deruxtecan (DATROWAY) is FDA‑approved for adult patients with locally advanced or metastatic EGFR‑mutated non‑small cell lung cancer (NSCLC) who have received prior EGFR‑directed therapy and platinum‑based chemotherapy. The indication received accelerated approval based on objective response rate and duration of response observed in the pooled TROPION‑Lung05 and TROPION‑Lung01 analyses. Continued approval may depend on verification of clinical benefit in a confirmatory trial.

Q2 How does datopotamab deruxtecan work?

Datopotamab deruxtecan is a Trop‑2‑directed antibody‑drug conjugate composed of a humanized anti‑Trop‑2 IgG1 linked to a potent topoisomerase I inhibitor payload (DXd). After binding Trop‑2 on tumor cells, the ADC is internalized and the linker is cleaved intracellularly, releasing the membrane‑permeable DXd payload that causes DNA damage and apoptotic tumor cell death. Preclinical models showed activity in lung and breast cancer models, and the clinical program demonstrated response in EGFR‑mutated NSCLC.

Q3 What is the recommended dosing for DATROWAY?

The FDA‑approved dosage of DATROWAY is 6 mg/kg administered as an intravenous infusion once every 3 weeks (21‑day cycle), up to a maximum of 540 mg for patients ≥90 kg, given until disease progression or unacceptable toxicity. The prescribing information specifies reconstitution, dilution in 5% dextrose injection, premedication for infusion reaction and nausea, ophthalmic evaluations, and dose modification rules for adverse reactions; clinicians should consult the full prescribing information for complete preparation and administration details.

Q4 What are the most important side effects clinicians should watch for?

Key adverse events reported in trials and in the prescribing information include interstitial lung disease/pneumonitis, which can be severe or fatal and requires monitoring and prompt management; stomatitis/oral mucositis, which was common (any grade 56.2% in TROPION‑Lung05) and led to dose holds or modifications; ocular adverse reactions including dry eye and keratitis, with recommended ophthalmic monitoring; and a spectrum of hematologic and nonhematologic toxicities (for example, decreased hemoglobin, decreased lymphocytes, nausea, alopecia, fatigue, elevated liver enzymes) that were reported at clinically meaningful rates. In TROPION‑Lung05, grade ≥3 treatment‑related adverse events occurred in 28.5% of patients and adjudicated treatment‑related ILD/pneumonitis occurred in 3.6% of patients with one (0.7%) grade 5 event. Clinicians should monitor for these events and follow the labeled dose modification and discontinuation guidance.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves datopotamab deruxtecan for EGFR‑mutant NSCLC: 45% ORR

FDA Approves datopotamab deruxtecan for EGFR‑mutant NSCLC: 45% ORR

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Oncology in your inbox.

Related Clinical Updates

FDA Approves relacorilant for Platinum-Resistant Ovarian Cancer; PFS HR 0.70 (ROSELLA)

FDA Approves vepdegestrant for ESR1‑Mutated ER+ HER2‑ Breast Cancer; PFS HR 0.58 in VERITAC‑2

Bispecific Antibodies in Oncology: Mechanisms and Approved Indications

Verified HCP Portal